NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

380.05 5.60 (1.50%)

30.60% Gain from 52W Low

7.0M NSE+BSE Volume

NSE 04 Jul, 2025 3:31 PM (IST)

50,811.3

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Dividend

Biocon Ltd. last dividend of ₹0.50 per share was given on 04 Jul 2025 See details

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Search Inside the pdf :

Biocon Ltd.

03 May 2025, 12:00AM

380.05

1.50%

Pick of the Week:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We recommend BUY with TP of Rs 351, which implies an upside of 10% from the current market price (CMP).

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

01 Feb 2025

380.05

1.50%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 405/share, implying a 12% upside potential from CMP

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

13 Jan 2025

380.05

1.50%

‘VAI’ status for Malaysian site provides regulatory boost

Buy: Biocon Ltd.

Recommendation Target

Motilal Oswal

Biocon (BIOS) has received ‘Voluntary Action Indicated’ (VAI) status for its Malaysian site. With this, BIOS now has all critical sites for biosimilars under USFDA compliance, improving its business prospects in the US market.

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

20 Nov 2024

380.05

1.50%

BIOCON LTD

Accumulate: Biocon Ltd.

Target

Geojit BNP Paribas

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

12 Nov 2024

380.05

1.50%

Soft quarter, expect recovery in H2

Buy: Biocon Ltd.

Sharekhan

Revenues stood at Rs. 3,590 crore, up 4% y-o-y and a 5% rise q-o-q. EBITDA reached Rs. 730 crore, down 1% y-o-y but up 24% q-o-q. PAT stood at Rs. 27 crore, a decline of 84% y-o-y and 97% q-o-q.

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

31 Oct 2024

380.05

1.50%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

09 Aug 2024

380.05

1.50%

Result Update:Biocon

Buy: Biocon Ltd.

Axis Direct

We have BUY on the stock

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

05 Aug 2024

380.05

1.50%

Pick of the Week:05 AUGUST 2024

Buy: Biocon Ltd.

Target

Axis Direct

We recommend BUY With TP OF RS 390 which implies an upside of 10% from the current market price (CMP).

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

28 Jun 2024

380.05

1.50%

GLP product launch a big opportunity

Buy: Biocon Ltd.

Target

Sharekhan

Biocon recently signed an exclusive licensing and supply agreement with Handok, a South Korean specialty pharma company for commercialization of synthetic liraglutide.